Literature DB >> 20677092

Blood compatibility of enveloped viruses.

Gray Kueberuwa1, Ryan Cawood, Leonard W Seymour.   

Abstract

A significant limitation to the use of viruses as systemic vectors is the susceptibility of the vector to inactivation and clearance by various blood components. Despite much focus on antibodies as the primary neutralizing molecules in blood, other mechanisms inactivate and clear virus particles from the bloodstream in both naïve and pre-immune hosts. This review provides an overview of the major blood components that interact with enveloped viruses. The mechanisms of action of these blood components by which virus particles are inactivated are also discussed. In addition, important blood components that act as barriers to the systemic delivery of therapeutic viruses are identified, and recent advances in overcoming these barriers are highlighted. Particular attention is given to the field of oncolytic virotherapy in which adequate intravenous virus delivery is critical for therapeutic success.

Mesh:

Substances:

Year:  2010        PMID: 20677092

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  7 in total

Review 1.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

Review 2.  Immunotherapeutic potential of oncolytic vaccinia virus.

Authors:  Steve H Thorne
Journal:  Immunol Res       Date:  2011-08       Impact factor: 4.505

3.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

4.  Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.

Authors:  Y-P Liu; C Tong; A Dispenzieri; M J Federspiel; S J Russell; K-W Peng
Journal:  Cancer Gene Ther       Date:  2011-11-25       Impact factor: 5.987

5.  Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.

Authors:  Joselle Cook; Kah-Whye Peng; Thomas E Witzig; Stephen M Broski; Jose C Villasboas; Jonas Paludo; Mrinal Patnaik; Vincent Rajkumar; Angela Dispenzieri; Nelson Leung; Francis Buadi; Nora Bennani; Stephen M Ansell; Lianwen Zhang; Nandakumar Packiriswamy; Baskar Balakrishnan; Bethany Brunton; Marissa Giers; Brenda Ginos; Amylou C Dueck; Susan Geyer; Morie A Gertz; Rahma Warsame; Ronald S Go; Suzanne R Hayman; David Dingli; Shaji Kumar; Leif Bergsagel; Javier L Munoz; Wilson Gonsalves; Taxiarchis Kourelis; Eli Muchtar; Prashant Kapoor; Robert A Kyle; Yi Lin; Mustaqeem Siddiqui; Amie Fonder; Miriam Hobbs; Lisa Hwa; Shruthi Naik; Stephen J Russell; Martha Q Lacy
Journal:  Blood Adv       Date:  2022-06-14

Review 6.  Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment.

Authors:  Ling Yang; Qian Ning; Sheng-Song Tang
Journal:  J Immunol Res       Date:  2022-03-18       Impact factor: 4.818

Review 7.  White paper on microbial anti-cancer therapy and prevention.

Authors:  Neil S Forbes; Robert S Coffin; Liang Deng; Laura Evgin; Steve Fiering; Matthew Giacalone; Claudia Gravekamp; James L Gulley; Hal Gunn; Robert M Hoffman; Balveen Kaur; Ke Liu; Herbert Kim Lyerly; Ariel E Marciscano; Eddie Moradian; Sheryl Ruppel; Daniel A Saltzman; Peter J Tattersall; Steve Thorne; Richard G Vile; Halle Huihong Zhang; Shibin Zhou; Grant McFadden
Journal:  J Immunother Cancer       Date:  2018-08-06       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.